Comparison of HPV test versus conventional and automation‐assisted Pap screening as potential screening tools for preventing cervical cancer
- 16 July 2004
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 111 (8) , 842-848
- https://doi.org/10.1111/j.1471-0528.2004.00210.x
Abstract
To evaluate new techniques in primary cervical cancer screening programmes. Cross sectional pilot study. Department of Obstetrics and Gynaecology, Helsinki University Hospital. Consecutive 2032 human papillomavirus (HPV) DNA and Pap smear samples were taken. Histological diagnoses were obtained from 460 patients. We compared the validity of the high risk (HR) HPV DNA detection test to automation-assisted and conventional Pap smear screening. Specificity and sensitivity of screening methods. Twenty-three percent of women were HPV positive. Forty-five of 46 had high grade lesions and cancers were HR HPV DNA positive, whereas 72/93 of low grade and more severe lesions were HR HPV DNA positive. When histologically verified high grade lesions were observed, the relative sensitivity of HR Hybrid Capture 2 (HR HC2) test was 98% compared with conventional Pap smear and Papnet tests, which performed 54%versus 58%, 83%versus 86% and 93%versus 98% relative sensitivity respectively, using cytological diagnoses HSIL (high grade squamous intraepithelial lesion), LSIL (low grade squamous intraepithelial lesion) or ASCUS (atypical squamous cells of undetermined significance) as the cutoff. The specificity of HC2 test (77-79%) was comparable with the ASCUS+ (ASCUS and more severe) cytology (68-79%), but lower when compared with LSIL+ (91-95%) or especially HSIL+ (97-99%) Pap smear results. Pap smear, as a screening test, is very different from HPV DNA detecting test HR HC 2. If cutoff LSIL or more severe lesions is used, primary Pap smear is clearly more specific than HR HC2, but markedly less sensitive. Due to high relative sensitivity of the HPV, only very few histologically confirmed high grade lesions would be detected among HPV negatives using simultaneous cytology. On the other hand, using HPV DNA test alone would lead to multifold amounts of referrals for colposcopy. A posterior Pap smear assessment among HPV positives might be helpful in increasing sensitivity and specificity of screening and defining those who need an immediate referral or treatment. We plan to incorporate primary HR HPV DNA test with posterior Pap smear reading of HPV positives into our ongoing randomised prospective multiarm trial evaluating new techniques in organised screening for cervical cancer in Finland.Keywords
This publication has 15 references indexed in Scilit:
- Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial NeoplasiaJNCI Journal of the National Cancer Institute, 2004
- Management of women who test positive for high-risk types of human papillomavirus: the HART studyThe Lancet, 2003
- Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort AnalysisJNCI Journal of the National Cancer Institute, 2003
- Prospective and randomised public‐health trial on neural network‐assisted screening for cervical cancer in Finland: Results of the first yearInternational Journal of Cancer, 2002
- Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA‐positive, cytologically negative womenCancer, 2002
- Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical AbnormalitiesJAMA, 2002
- Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 womenBritish Journal of Cancer, 2001
- Human Papillomavirus Testing for Triage of Women With Cytologic Evidence of Low-Grade Squamous Intraepithelial Lesions: Baseline Data From a Randomized TrialJNCI Journal of the National Cancer Institute, 2000
- The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteriObstetrics & Gynecology, 1995
- TRENDS IN MORTALITY FROM CERVICAL CANCER IN THE NORDIC COUNTRIES: ASSOCIATION WITH ORGANISED SCREENING PROGRAMMESThe Lancet, 1987